Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Kodiak Gas Services Inc. Common Stock (KGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Kodiak Gas Services Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Kodiak Gas Services Inc. Common Stock trades at $50.07 (market cap $5.26B). The key difference: Kodiak Gas Services Inc. Common Stock is the larger of the two by market cap, and Kodiak Gas Services Inc. Common Stock pays a 3.77% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Kodiak Gas Services Inc. Common Stock for 6 Days on average.
| DYN | KGS | |
|---|---|---|
Market Cap | $2.86B | $5.26B |
Volume | 3,341,579 | 2,807,958 |
Sector | Health | Energy |
52-Week High | $26.78 | $76.27 |
52-Week Low | $14.60 | $32.95 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.18B | $7.94B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KGS trades at $52.00, down 0.93% on the day, with technical indicators showing a bearish trend. The company reported Q2 2026 revenue growth but missed earnings expectations for three consecutive quarters. Recent developments include a significant power supply agreement for West Texas data centers, positioning KGS for future growth in distributed power generation.
Despite recent earnings misses, analyst consensus remains strongly bullish with a $80.38 price target representing 55% upside potential. Key risks include execution challenges in expanding power capacity and continued earnings volatility. The company's strategic pivot toward data center power services offers substantial growth opportunity if successfully executed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Kodiak Gas Services Inc. Common Stock
Kodiak Gas Services, Inc. is a Texas-based provider of large-horsepower contract natural gas compression services, operating a fleet of roughly 4.5 million revenue-generating horsepower for oil and gas producers and midstream companies across major US production basins, including the Permian, Eagle Ford, and DJ Basin.
Read more on KGS →
